MREO Mereo BioPharma Group plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1719714 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY35.2%
TTM EPS YoY40.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-76.6%
ROA-64.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets19.8%
Debt / equity0.00x
Current ratio5.22x
Interest coverage-440.64x
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $800,000 | $0 | — | $0 | $0 | $500,000 | — | $0 |
| R&D expense | $2.09M | $1.81M | $4.75M | $4.19M | $4.27M | $5.37M | $3.93M | $8.82M |
| SG&A expense | $4.93M | $5.22M | $4.02M | $4.20M | $6.04M | $5.49M | $7.27M | $6.45M |
| Operating income | -$6.22M | -$7.03M | -$8.77M | -$8.39M | -$10.02M | -$10.50M | -$11.20M | -$15.28M |
| Interest expense | $10,000 | $16,000 | $20,000 | $23,000 | $28,000 | $24,000 | $180,000 | $375,000 |
| Pretax income | -$5.86M | -$7.00M | -$6.72M | -$7.35M | -$7.02M | -$14.62M | -$12.89M | -$7.05M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$5.86M | -$7.00M | -$6.72M | -$7.35M | -$7.02M | -$14.62M | -$12.89M | -$7.05M |
| EBITDA | -$6.19M | -$6.99M | -$8.72M | -$8.35M | -$9.98M | -$10.46M | -$11.16M | -$15.24M |
| EPS (basic) | -0.01 | -0.01 | -0.01 | — | -0.01 | -0.02 | -0.02 | — |
| EPS (diluted) | -0.01 | -0.01 | -0.01 | — | -0.01 | -0.02 | -0.02 | — |
| Weighted avg. shares (diluted) | 804.53M | 803.56M | 801.81M | — | 799.95M | 799.44M | 784.28M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $26.10M | $30.12M | $30.10M | $40.99M | $48.70M | $56.12M | $62.48M | $69.80M |
| Current assets | $28.67M | $33.40M | $40.03M | $45.02M | $52.41M | $61.42M | $66.90M | $74.76M |
| PP&E, net | $24,000 | $54,000 | $91,000 | $137,000 | $174,000 | $218,000 | $247,000 | $257,000 |
| Intangibles | $129,000 | $256,000 | $381,000 | $516,000 | $643,000 | $470,000 | $554,000 | $643,000 |
| Total assets | $29.58M | $34.71M | $40.61M | $45.92M | $53.60M | $62.63M | $68.32M | $76.39M |
| Current liabilities | $5.49M | $5.68M | $6.18M | $4.30M | $6.02M | $7.56M | $7.50M | $13.85M |
| Total liabilities | $5.87M | $6.06M | $6.56M | $5.00M | $7.00M | $8.45M | $8.24M | $15.42M |
| Shareholders' equity | $23.71M | $28.65M | $34.05M | $40.92M | $46.60M | $54.18M | $60.08M | $60.97M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.05M | -$6.04M | -$4.31M | -$7.68M | -$7.31M | -$7.65M | -$8.33M | -$9.42M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 | $0 | $20,000 | $0 |
| Free cash flow | -$4.05M | -$6.04M | -$4.31M | -$7.68M | -$7.31M | -$7.65M | -$8.35M | -$9.42M |
| Investing cash flow | $0 | $0 | -$300,000 | $0 | $300,000 | $0 | -$320,000 | $0 |
| Financing cash flow | $0 | $0 | $0 | $39,000 | $0 | -$134,000 | $422,000 | -$40,000 |
| Depreciation & amortization | $30,000 | $38,000 | $44,000 | $36,000 | $39,000 | $44,000 | $38,000 | $38,000 |
| Stock-based compensation | $909,000 | $1.32M | $1.60M | $1.54M | $1.71M | $2.06M | $2.28M | $1.51M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.